Trial Profile
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2886721 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 13 Jun 2013 Status changed from recruiting to discontinued, according to an Eli Lilly and Company media release. The decision to terminate the study was due to abnormal liver biochemical tests.
- 06 Jun 2013 Planned end date changed from 1 Feb 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 21 Nov 2012 Planned End Date changed from 1 Jan 2015 to 1 Feb 2014 as reported by ClinicalTrials.gov.